We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
Novavax (NVAX - Free Report) ended the recent trading session at $8.46, demonstrating a -1.51% change from the preceding day's closing price. This change lagged the S&P 500's 0.53% loss on the day. Meanwhile, the Dow experienced a drop of 0.71%, and the technology-dominated Nasdaq saw a decrease of 0.93%.
The stock of vaccine maker has fallen by 0.92% in the past month, lagging the Medical sector's gain of 3.64% and the S&P 500's gain of 1.13%.
The investment community will be paying close attention to the earnings performance of Novavax in its upcoming release. On that day, Novavax is projected to report earnings of -$0.44 per share, which would represent year-over-year growth of 42.11%. Simultaneously, our latest consensus estimate expects the revenue to be $67 million, showing a 20.72% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.56 per share and revenue of $1.03 billion, indicating changes of +308.13% and +51.52%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Novavax. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 4.55% fall in the Zacks Consensus EPS estimate. At present, Novavax boasts a Zacks Rank of #3 (Hold).
Investors should also note Novavax's current valuation metrics, including its Forward P/E ratio of 3.36. This valuation marks a discount compared to its industry average Forward P/E of 20.42.
It is also worth noting that NVAX currently has a PEG ratio of 0.11. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.67 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 92, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
Novavax (NVAX - Free Report) ended the recent trading session at $8.46, demonstrating a -1.51% change from the preceding day's closing price. This change lagged the S&P 500's 0.53% loss on the day. Meanwhile, the Dow experienced a drop of 0.71%, and the technology-dominated Nasdaq saw a decrease of 0.93%.
The stock of vaccine maker has fallen by 0.92% in the past month, lagging the Medical sector's gain of 3.64% and the S&P 500's gain of 1.13%.
The investment community will be paying close attention to the earnings performance of Novavax in its upcoming release. On that day, Novavax is projected to report earnings of -$0.44 per share, which would represent year-over-year growth of 42.11%. Simultaneously, our latest consensus estimate expects the revenue to be $67 million, showing a 20.72% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.56 per share and revenue of $1.03 billion, indicating changes of +308.13% and +51.52%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Novavax. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 4.55% fall in the Zacks Consensus EPS estimate. At present, Novavax boasts a Zacks Rank of #3 (Hold).
Investors should also note Novavax's current valuation metrics, including its Forward P/E ratio of 3.36. This valuation marks a discount compared to its industry average Forward P/E of 20.42.
It is also worth noting that NVAX currently has a PEG ratio of 0.11. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.67 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 92, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.